, Volume 121, Issue 1, pp 104–108 | Cite as

Benzodiazepine (ω) receptor partial agonists and the acquisition of conditioned fear in mice

  • D. J. Sanger
  • D. Joly
  • G. Perrault
Original Investigation


It is well established that benzodiazepines can produce anterograde amnesia in humans and interfere with the acquisition of passive avoidance and spatial responses in rodents. However, the extent to which the disruption of learning is a secondary effect of the sedation produced by these drugs has not been clearly established. In order to investigate this question, the effects of several BZ (ω) receptor partial agonists were studied on the acquisition of conditioned fear (passive avoidance learning) in mice. As these drugs have been shown to produce anticonvulsant and anxiolytic-like effects without sedation or depression of motor activity, it was of interest to see whether they could disrupt learning. Clear effects on the acquisition of conditioned fear were produced by imidazenil (0.01–1.0 mg/kg), divaplon (1–60 mg/kg), ZK 91296 (3–60 mg/kg), and Ro 17-1812 (0.1–10 mg/kg). However, bretazenil (0.1–10 mg/kg) did not produce statistically significant effects. Only the high dose of imidazenil (1.0 mg/kg) decreased levels of exploratory behaviour. These results show that BZ (ω) receptor partial agonists without apparent sedative actions can disrupt fear learning, indicating that the effects of this class of drugs on passive avoidance learning can be dissociated from sedation. The reasons for the observed differences between the different compounds studied are unclear at present and may be related to differences in intrinsic activity or receptor subtype selectivity.

Key words

Conditioned fear Imidazenil Divaplon ZK 91296 Ro 17-1812 Bretazenil Mice 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Broekkamp CL, Le Pichon M, Lloyd KG (1984) The comparative effects of benzodiazepines, progabide and PK 9084 on acquisition of passive avoidance in mice. Psychopharmacology 83:122–125Google Scholar
  2. Crawley JN, Goodwin FK (1980) Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13:167–170Google Scholar
  3. Curran HV (1986) Tranquillising memories: a review of the effects of benzodiazepines on human memory. Biol Psychol 23:179–213Google Scholar
  4. Deacon RMJ, Guy AP, Gardner CR (1991) Effects of selected imidazopyridine ligands for benzodiazepine receptors in rodent models of anxiety and behavioural impairment. Drug Dev Res 22:321–329Google Scholar
  5. Gardner CR, Tully WR, Hedgecock CJR (1993) The rapidly expanding range of neuronal benzodiazepine receptor ligands. Prog Neurobiol 40:1–61.Google Scholar
  6. Ghoneim MM, Mewaldt SP, Berie JL, Hinrichs JV (1981) Memory and performance effects of single and 3-week administration of diazepam. Psychopharmacology 73:147–151Google Scholar
  7. Giusti P, Ducic I, Puia G, Arban R, Walser A, Guidotti A, Costa E (1993) Imidazenil: a new partial positive allosteric modulator ofγ-aminobutyric acid (GABA) action at GABAA receptors. J Pharmacol Exp Ther 266:1018–1028Google Scholar
  8. Griebel G, Belzung C, Misslin R, Vogel E (1993) The free-exploratory paradigm: an effective method for measuring neophobia behaviour in mice and testing potential neophobia-reducing drugs. Behav Pharmacol 4:637–644Google Scholar
  9. Haefely W (1984) Pharmacological profile of two benzodiazepine partial agonists: Ro 16-6028 and Ro 17-1812. Clin Neuropharmacol 7, [Suppl 1]:670–671Google Scholar
  10. Haefely W, Martin JR, Schoch P (1990) Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci 11:452–456Google Scholar
  11. King DS (1992) Benzodiazepines, amnesia and sedation: theoretical and clinical issues and controversies. Human Psychopharmacol 7:79–87Google Scholar
  12. Knoflach F, Drescher U, Scheurer L, Malherbe P, Mohler H (1993) Full and partial agonism displayed by benzodiazepine receptor ligands at recombinantγ-aminobutyric acidA receptor subtypes. J Pharmacol Exp Ther 266:385–391Google Scholar
  13. Lister RG (1985) The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev 9:87–94Google Scholar
  14. Lucki I, Rickels K, Geller AM (1986) Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology 88:426–433Google Scholar
  15. Martin JR, Pieri L, Bonetti EP, Schaffner R, Burkard WP, Cumin R, Haefely WE (1988) Ro 16-6028: a novel anxiolytic acting as a partial agonist at the benzodiazepine receptor. Pharmacopsychiatry 21:360–362Google Scholar
  16. Martin JR, Schoch P, Jenck F, Moreau JL, Haefely WE (1993) Pharmacological characterization of benzodiazepine receptor ligands with intrinsic efficacies ranging from high to zero. Psychopharmacology 11:415–422Google Scholar
  17. McNamara RK, Skelton RW (1992) Like diazepam, CL 218,872, a selective ligand for the benzodiazepineω 1 receptor subtype, impairs place learning in the Morris water maze. Psychopharmacology 107:347–351Google Scholar
  18. McNaughton N, Morris RGM (1987) Chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. Behav Brain Res 24:39–46Google Scholar
  19. Patel JB, Ciofalo, VB, Iorio LC (1979) Benzodiazepine blockade of passive-avoidance task in mice: a state-dependent phenomenon. Psychopharmacology 61:25–28Google Scholar
  20. Petersen EN, Jensen LH, Honore T, Braestrup C, Kehr W, Stephens DW, Wachtel H, Seidelman D, Schmiechen R (1984) ZK 91296, a partial agonist at benzodiazepine receptors. Psychopharmacology 83:240–248Google Scholar
  21. Potier MC, Prado de Carvalho L, Venault P, Chapouthier G, Rossier J (1988) Demonstration of the partial agonist profiles of Ro 16-6028 and Ro 17-1812 in mice in vivo. Eur J Pharmacol 156:169–172Google Scholar
  22. Puia G, Ducic I, Vicini S, Costa E (1992) Molecular mechanisms of the partial allosteric modulatory effect of bretazenil atγ-aminobutyric acid type A receptor. Proc Natl Acad Sci 89:3620–3624Google Scholar
  23. Sanger DJ, Joly D (1985) Anxiolytic drugs and the acquisition of conditioned fear in mice. Psychopharmacology 85:284–288Google Scholar
  24. Sanger DJ, Joly D, Zivkovic B (1986) Effects of zolpidem, a new imidazopyrdine hypnotic, on the acquisition of conditioned fear in mice. Comparison with triazolam and CL 218,872. Psychopharmacology 90:207–210Google Scholar
  25. Sanger DJ, Joly D, Zivkovic B (1993) Anxiolytic drugs and cognitive function. In: Hamon M, Ollat H, Thiebot MH (eds) Anxiety: neurobiology, clinic and therapeutic perspectives. John Libbey, London, pp 119–128Google Scholar
  26. Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, Zivkovic B (1994) Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 18:355–372Google Scholar
  27. Serra M, Ghiani CA, Motzo C, Cuccheddu T, Floris S, Giusti P, Biggio G (1994) Imidazenil, a new partial agonist of benzodiazepine receptors, reverses the inhibitory action of isoniazid and stress onγ-aminobutyric acidA receptor function. J Pharmacol Exp Ther 269:32–38Google Scholar
  28. Tang AH, Franklin SR, Himes CS and Ho PM (1991) Behavioral effects of U-7887, a quinoxalinone anxiolytic with potent benzodiazepine antagonist activity. J Pharmacol Exp Ther 259:248–254Google Scholar
  29. Task Force of the Collegium Internationale Neuro-Psychopharmacologicum (CINP) (1992) Impact of neuropharmacology in the 1990s-treatment strategies for anxiety disorders and insomnia. Eur Neuropsychopharmacol 2:167–169Google Scholar
  30. Wada T, Fukuda N (1992) Effect of a new anxiolytic, DN-2327, on learning and memory in rats. Pharmacol Biochem Behav 41:573–579Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • D. J. Sanger
    • 1
  • D. Joly
    • 1
  • G. Perrault
    • 1
  1. 1.Synthélabo Recherche.BagneuxFrance

Personalised recommendations